Four Ways Stem Cells Will Change the Face of Medicine

• The California Institute for Regenerative Medicine (CIRM) was established in 2010 via Proposition 71 with a $3 billion taxpayer fund, having allocated approximately $2.2 billion over 10 years to research across 39 incurable diseases.
• CIRM has funded approximately 65 entities, including medical schools, research institutes (Gladstone, Salk, Scripps), and biotech companies, bridging the "Valley of Death" between speculative basic research and commercial viability.
• A significant shift in public perception regarding embryonic stem cells has occurred, with polls indicating 60-70% of the public now view the research favorably, attributed to increased scientific education and the historical normalization of controversial reproductive technologies like IVF.
• The "Valley of Death" in funding remains a critical bottleneck as NIH funding for early-stage regenerative research has diminished, leading to the recent discontinuation of the NIH Center for Regenerative Medicine.
• Current research is being driven by partnerships between academic institutions and small biotech firms (e.g., Sangamo Biosciences) funded by CIRM to overcome the high costs and regulatory hurdles of translating cell therapies.

Therapeutic Developments and Clinical Timelines

Embryonic Stem Cells (Dr. Eugene Brandon, Viacyte)

• Current focus is on differentiating embryonic stem cells into pancreatic islet cells to treat Type 1 diabetes, replacing the need for scarce cadaveric organ transplants.
• Treatment strategy involves encapsulating derived cells in a "high-tech tea bag" device that allows oxygen and glucose exchange while protecting the cells from immune rejection, eliminating the need for lifelong immunosuppressants.
• Clinical trials for this approach are projected to yield data within the next few years, with broader stem cell applications for organ replacement expected to emerge in 5 to 10 years.
• By 2020, the panel anticipates seeing results from Phase II trials for retinal treatments and neural stem cell trials for ALS, marking a significant acceleration in therapy development.

Gene Therapy and Stem Cell Combinations (Dr. Paula Cannon, USC)

• Research is applying zinc finger nucleases (molecular scissors) to edit a patient's own hematopoietic stem cells to remove the CCR5 gene, rendering the resulting immune system resistant to HIV.
• A $14 million CIRM-funded project has successfully demonstrated in humanized mouse models that edited stem cells can clear HIV from the system within three months.
• Regulatory filings (IND) with the FDA are underway, with the project team optimistic about initiating clinical trials later in the year.
• This approach, combined with established bone marrow transplant history, is viewed as a potential gold standard for curing immune disorders and sickle cell disease.

Autologous Stem Cell Activation (Dr. Jill Helms, Stanford)

• Strategy involves harvesting a patient's own bone marrow and treating it with the Wnt3a protein ex vivo to reverse the aging effects on skeletal stem cells, thereby enhancing bone regeneration.
• Preclinical data indicates that Wnt3a treatment reduces cell death and stimulates cell division in bone grafts, resulting in superior bone formation compared to standard autografts in rabbit models.
• The project aims to file for FDA approval in approximately 5 to 6 years, leveraging the existing safety profile of protein therapeutics and autologous cell sourcing.

Disease Modeling and Drug Screening (Dr. Alison Watry, UCSD)

• Research utilizes induced pluripotent stem cells (iPSCs) derived from the dental pulp of autistic patients to create neuron models in a dish for studying disease pathology.
• Distinct structural differences were observed in autistic neurons, specifically reduced synaptic spines, which were successfully reversed in vitro by treating cells with experimental drugs.
• This "disease-in-a-dish" model offers the fastest track to drug discovery, potentially allowing for the repurposing of existing drugs (e.g., Alzheimer's medications) for autism within a year, or 5-10 years for novel drug development.

Challenges, Risks, and Future Directions

• Stem Cell Tourism: The panel warns against unregulated "stem cell tourism" clinics, noting that desperate patients seeking cures are often exploited by charlatans offering unproven treatments; patients are urged to verify if trials are published in peer-reviewed journals and regulated by national bodies.
• Cost and Accessibility: While cell therapies may be expensive, they could become cost-effective over time by offering long-lasting cures compared to lifelong daily drug injections; historical trends in genomics suggest costs will decrease significantly as technology matures.
• Next Generation Applications: The panel predicts a major future advancement in in vivo reprogramming, where aging cells are reversed directly within the body to decelerate aging, a concept aligning with the goals of companies like Calico (funded by Google).
• Funding Sustainability: CIRM faces a projected exhaustion of its $3 billion fund within three years, necessitating urgent identification of alternative funding sources to prevent the collapse of a critical research infrastructure that currently leads global regenerative medicine efforts.